← Back to Clinical Trials
Recruiting NCT05837767

A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Invasive Ductal Breast Carcinoma
Sponsor Memorial Sloan Kettering Cancer Center
Study Type INTERVENTIONAL
Phase N/A
Enrollment 26
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2023-07-24
Completion 2026-07-24
Interventions
Palliative radiotherapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The purpose of this study is to find out whether lattice radiation therapy (LRT) is an effective radiation therapy technique when compared to standard stereotactic body radiation therapy (SBRT). The study will also study how the different radiation therapy techniques (LRT and SBRT) affect how many immune cells are able to attack and kill tumor cells (immune infiltration).

Eligibility Criteria

Inclusion Criteria: * Patients with biopsy confirmed advanced/metastatic solid tumors of the following types: invasive ductal or lobular breast carcinoma (all histological and intrinsic subtypes), non-small cell lung cancer (NSCLC, all subtypes), gastrointestinal squamous cell or adenocarcinomas (including pancreatic cancer), bladder cancer, renal cell carcinoma, melanoma, and soft tissue sarcoma (all subtypes), who require and are being planned for palliative radiation therapy to at least one site of extracranial metastatic disease measuring at least 5 cm in a single axis. If a patient, requires palliative radiotherapy to additional sites, these can be treated with standard of care SBRT per departmental guidelines. * Age ≥ 18 years * ECOG Performance Status of 0 or 1. Exclusion Criteria: * Patients who are pregnant or breastfeeding * Prior radiation therapy to the candidate metastatic sites under consideration for treatment ("re-irradiation" is disallowed). * Medical condition such as

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}